Skip to main content
medichelpline
Join Free
Back to Drug Index
General MedicationsINHALATIONStandard

ADVAIR HFA

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

Standard Dose
0.045MG/INH;EQ 0.021MG BASE/INH
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription

Key Takeaways

  • Primary indication: Review priority: STANDARD Marketing status: Prescription
  • Approval overview ADVAIR HFA is listed in Drugs@FDA under application 021254 (NDA).
  • Review priority: STANDARD Marketing status: Prescription Active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE Form and strength AEROSOL, METERED;INHALATION - 0.045MG/INH;EQ 0.021MG BASE/INH Sponsor GLAXO GRP LTD Submission history Latest submission status date: 2021-08-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview ADVAIR HFA is listed in Drugs@FDA under application 021254 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE Form and strength AEROSOL, METERED;INHALATION - 0.045MG/INH;EQ 0.021MG BASE/INH Sponsor GLAXO GRP LTD Submission history Latest submission status date: 2021-08-18 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.